Scarica l'app Stockscreener
255.00
1.63%
4.09
Dopo l'orario di chiusura:
255.81
0.81
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie stock heads into the open after a 1.6% gain - ad-hoc-news.de
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH - The Motley Fool
AbbVie Share Price Today (ABBV) | Live Chart, News & Stock Market - TechGraph
Abbvie Declares Quarterly Dividend, Payable on November 16, 2026 - marketscreener.com
AbbVie declares quarterly dividend of $1.73 per share - Investing.com
AbbVie declares quarterly dividend of $1.73 per share By Investing.com - Investing.com India
AbbVie Gains as Qulipta Opens a New Migraine Market - Yahoo! Finance Canada
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine - Investing News Network
AbbVie reports positive Phase 3 migraine trial results - grafa.com
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - Benzinga
AbbVie Inc. stock gains as atogepant trial success and HSBC target hike reinforce growth story - ad-hoc-news.de
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - Yahoo Finance
ABBV Maintained by HSBC -- Price Target Raised to $315 - GuruFocus
AbbVie's menstrual migraine treatment meets late-stage study goal - Reuters
Why Has AbbVie Gone Quiet About Humira? - Trefis
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX) - Seeking Alpha
AbbVie’s migraine treatment meets late-stage study goal - 1450 AM 99.7 FM WHTC
AbbVie reports positive phase 3 trial for menstrual migraine drug By Investing.com - Investing.com Canada
No treatment is approved for menstrual migraine. AbbVie’s drug cut migraine days in a trial. - Stock Titan
UChicago Medicine names Kimyatta Washington Chief Operating Officer of AbbVie Foundation Cancer Pavilion | Newswise - Newswise
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth? - Yahoo Finance
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference - Yahoo Finance
AbbVie at Wells Fargo healthcare conference: growth beyond immunology By Investing.com - Investing.com UK
ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments - TradingView
AbbVie stock slips as Q2 revenue rises 10.2 percent - ad-hoc-news.de
AbbVie issues US$10 billion to fund Apogee acquisition - fi-desk.com
AbbVie stock heads into the open after a 2.99 percent drop - ad-hoc-news.de
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
Why Did AbbVie (NYSE:ABBV) Just Close Its Biggest Deal In Years? - Kalkine Media
Is AbbVie Stock Too Reliant On Skyrizi? - Trefis
AbbVie Inc. stock edges lower as investors weigh strong earnings and higher analyst targets - ad-hoc-news.de
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282 - Moomoo
BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $282 - Moomoo
BofA raises Abbvie stock price target on Apogee deal close By Investing.com - Investing.com India
BofA raises Abbvie stock price target on Apogee deal close - Investing.com
AbbVie’s Next Skyrizi Catalyst Lands This Fall. Here’s What’s at Stake for the Stock - TIKR.com
AbbVie Inc. (ABBV) Stock Analysis: Exploring Growth Potential Amidst A Solid 7.85% Upside - DirectorsTalk Interviews
What Does Friday’s Close Mean for AbbVie (NYSE:ABBV) and NYSE? - Kalkine Media
Mary Kuriakose Starts New Oncology Leadership Role at AbbVie - Oncodaily
AbbVie Inc. stock holds near highs as Apogee deal and guidance support sentiment - ad-hoc-news.de
Key deals this week: Flex, Nvidia, AbbVie and more (VRT:NYSE) - Seeking Alpha
Michael Henderson: A New Chapter Begins for Apogee Therapeutics With AbbVie - Oncodaily
Scotiabank Remains a Buy on AbbVie (ABBV) - The Globe and Mail
AbbVie-allied ADARx aims to go public with 3 drugs in the clinic - Endpoints News
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Trailing rivals, AbbVie scores win with dual-acting myeloma drug - BioPharma Dive
AbbVie Inc. stock gains on Apogee deal and reaffirmed 2026 guidance - ad-hoc-news.de
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study - Yahoo Finance
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing? - finance.yahoo.com
1.91%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):